Navigation Links
NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
Date:10/25/2007

EMERYVILLE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (Amex, TSX: NBY) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of U.S. $4.00 per share. NovaBay has granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover over-allotments, if any. The shares will commence trading on October 26, 2007 on the American Stock Exchange and on an "if, as and when issued" basis on the Toronto Stock Exchange, under the symbol "NBY". The offering is expected to close on or about October 31, 2007.

Dundee Securities Corporation is acting as the sole book runner for the offering, with Desjardins Securities Inc. as co-lead manager. The shares are being offered in Canada by an underwriting syndicate co-led by Dundee Securities Corporation and Desjardins Securities Inc. and including Blackmont Capital Inc., and in the United States by Dundee Securities Inc. and Dawson James Securities, Inc.

The offering is being made in the United States pursuant to a written prospectus forming a part of the registration statement relating to these securities, which was declared effective by the Securities and Exchange Commission on October 24, 2007, and in Canada pursuant to a final base PREP prospectus dated October 24, 2007 for which a receipt has been issued by the applicable Canadian securities regulatory authorities and which shall be supplemented by a supplemented PREP prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, and there shall be no sale of these securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province or jurisdiction.

Copies of the United States prospectus may be obtai
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Corn prices and ethanol: Are the markets flaky - or working as they should?
4. Alliant to add 100 megawatts of wind power by 2005, raise gas prices
5. QBIs PreserveX product passes initial test
6. 2006: A great biotech financing year, unless you were going public!
7. TomoTherapys 100th radiology system reaches public sector
8. With patents and research tools, when is private really public?
9. Brady Corp. raises $137 million in public offering
10. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
11. Republican sees nothing wrong with Doyles use of executive order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)...  Caris Life Sciences® today announced the presentation ... identified biomarker changes, including key driver mutations, in ... in response to therapy as the disease progresses. ... of a larger study analyzing 1,245 glioma samples ... data utilizing Caris Molecular Intelligence®, the company,s panomic ...
(Date:5/29/2015)... , May 29, 2015 BerGenBio ... today announces that an abstract on the latest data ... of the Axl receptor tyrosine kinase, and BGB10C9, an ... has been published in conjunction with the 2015 American ... Chicago , May 29 - June 2, ...
(Date:5/29/2015)... , May 29, 2015 ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading ... (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for ... the end of the decade.   New ...
(Date:5/29/2015)... 2015 When a leading manufacturer ... request to design an industrial oven ... medications being produced using a 3D-printing process, Gruenberg ... robotic gantry, heat-saving windows, and internal actuators and ... 3D-printed pills to exact specifications. , To ensure ...
Breaking Biology Technology:Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2
... Inc. (NYSE Alternext US: DDD) today reported financial results ... 2008. The Company will host a live conference ... Daylight Time)."Last year was an important period for SCOLR ... M.B.A. "Utilizing our unique CDT(R) platforms, we made significant ...
... Radiotherapy Department in State of Qatar to Introduce ... One of the leading cancer centers in ... devices from Varian Medical Systems (NYSE: ... and precise treatments. Al Amal Hospital in Doha, ...
... Neogen Corporation (Nasdaq: NEOG ) announces ... Results WebcastWhen: Thursday, March 19, 2009 @ ... Live over the Internet -- Simply log on ... Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333.If ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... toxic protein particles severely disrupt neurotransmission and inhibit delivery ... by Marine Biological Laboratory (MBL) researchers have found. ... has long been known to accumulate and form plaques ... small particles that haven,t aggregated into plaquesthese are increasingly ...
... Mutations in a gene may cause poor lung development in ... obstructive pulmonary disease (COPD) later in life, say researchers at ... the German Research Center for Environmental Health. Their study, published ... the gene and its variants in both mouse lungs and ...
... A University of Florida scientist whose interest in embryonic ... building blocks that shape appendages ranging from feet to ... Career Scientist today (Thursday, March 26), a distinction given ... Martin Cohn, a developmental biologist and a member of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2Changes in gene may stunt lung development in children 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Experion Pro260 analysis kit for 10 chips ... perform protein analysis with the Experion automated ... microfluidic chips, 3 x 520 microliters Pro260 ... Pro260 ladder (10-260 kD), 400 microliters Pro260 ...
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
Biology Products: